(VIANEWS) – Shares of AB SCIENCE Plunge 31.66% in Value Loss
About AB SCIENCE
AB Science S.A. is a pharmaceutical company focused on researching, developing and marketing protein kinase inhibitors for human and veterinary medicines. Their lead compound masitinib, a tyrosine kinase inhibitor currently in Phase III trials for multiple indications such as prostate and pancreatic cancer treatment; amyotrophic lateral sclerosis multiple sclerosis Alzheimer’s severe asthma mastocytosis diseases as well as Covid-19 treatment has entered Phase II trials as well. Additionally AB8939 synthetic microtubule destabilizer is being developed; founded in 2001 with headquarters located in Paris France
Yearly Analysis
Based on available information, AB SCIENCE’s stock is trading at EUR2.25, well below its 52-week high of EUR7.49 but above its 52-week low of EUR2.18 – this suggests it has experienced significant decrease in value over the last year.
Investors will want to review a company’s financial performance, growth prospects and industry trends when making investment decisions. Furthermore, investors may want to take into account factors like earnings, revenue and dividend yield as well as any recent news that may have an effect on its share performance.
Technical Analysis
AB SCIENCE’s stock price has experienced an abrupt fall, falling below both its 50-day and 200-day moving averages of EUR3.07 and EUR3.70, respectively. Recent performance has been marked by high intraday variation averages, which include negative 0.95% for intraday variation averages from last week through quarter, negative 0.83% in month 3 and positive 3.42% in quarter 3. Its highest amplitude average volatility ranged between 2.16% (week), 3.12% in month 3, and 3.42% overall.
As part of AB SCIENCE’s stock price classification, its stochastic oscillator, an indicator for overbought and oversold conditions, indicates that its stock may currently be considered overbought (>=80). Given its high amplitude volatility and overbought condition, this may be an indicator that suggests correction is imminent.
Note, however, that stock prices can be heavily impacted by external influences including company news, economic conditions and market sentiment. Therefore, investors must exercise extreme caution when making any investment decisions and conduct extensive research before making their choice.
Quarter Analysis
Revenue growth for this stock experienced a 28.8% year-over-year drop during its most recent quarter, totalling an annualized revenue total of 777k. This information signals to investors that revenue may no longer be growing as quickly, which should cause concern. It is worthwhile exploring why revenue is slowing and assess whether it is temporary or long-term trend; also compare this stock’s revenue growth against that of its competitors to gain insight into its overall financial performance and potential for future expansion.
Equity Analysis
Earnings per Share (EPS) is an essential metric used to assess a company’s financial performance, representing the amount of profit generated for every outstanding share. A negative EPS indicates a company has sustained losses over its trailing twelve month period; for AB SCIENCE this loss amounts to EUR-0.36; this indicates significant loss during that time frame.
Investors must take this negative EPS into account when evaluating a company’s financial health and future growth prospects. Investors should keep in mind that its earnings per share (EPS) can be affected by various factors including market conditions, competition and internal operational efficiency; thus they should consider various elements when making investment decisions.
More news about AB SCIENCE (AB.PA).
